BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
BioCentury | May 12, 2016
Translation in Brief

PET projects

...trials did not meet their primary endpoints and a third is ongoing. AC Immune has Tau-PET Imaging Agent...
Items per page:
1 - 2 of 2